Turner Syndrome

13
Pipeline Programs
6
Companies
8
Clinical Trials
1 recruiting
8
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
3
9
Early DiscoveryClinical DevelopmentMarket

On Market (8)

Approved therapies currently available

U
ESCLIMApproved
estradiol
Unknown Company
transdermal1998
U
GYNODIOLApproved
estradiol
Unknown Company
oral1997
U
IMVEXXYApproved
estradiol
Unknown Company
Estrogen [EPC]vaginal2018
Novo Nordisk
INNOFEMApproved
estradiol
Novo Nordisk
oral1999
U
SAIZENApproved
somatropin
Unknown Company
injection1996
U
SEROSTIMApproved
somatropin
Unknown Company
injection1996
U
SEROSTIM LQApproved
somatropin
Unknown Company
subcutaneous1996
Novo Nordisk
VAGIFEMApproved
estradiol
Novo Nordisk
Estrogen [EPC]vaginal1999

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
estradiolPhase 41 trial
Active Trials
NCT00134745Completed43Est. Mar 2013
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
1
17 beta estradiolPhase 31 trial
Turner Syndrome Prenatal Diagnosis StudyN/A1 trial
Active Trials
NCT01668251Unknown60Est. Jan 2017
NCT00140998Completed16Est. Jun 2004
Ascendis Pharma
Ascendis PharmaCA - Palo Alto
2 programs
1
1
Lonapegsomatropin [SKYTROFA®]Phase 31 trial
LonapegsomatropinPhase 21 trial
Active Trials
NCT05690386Active Not Recruiting48Est. Dec 2027
NCT07221851Recruiting186Est. Mar 2029
Ipsen
IpsenChina - Tianjin
1 program
1
SomatropinPhase 31 trial
Active Trials
NCT00234533Completed251Est. Jul 2008
AB
AP BiosciencesTaiwan - Taipei
1 program
X-chromosome Inactivation, Epigenetics and the TranscriptomeN/A1 trial
Active Trials
NCT01678261CompletedEst. Jan 2016
Pfizer
PfizerNEW YORK, NY
1 program
somatotropinN/A1 trial
Active Trials
NCT01367834Completed17Est. May 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Novo Nordiskestradiol
Ascendis PharmaLonapegsomatropin [SKYTROFA®]
IpsenSomatropin
Eli Lilly and Company17 beta estradiol
Ascendis PharmaLonapegsomatropin
AP BiosciencesX-chromosome Inactivation, Epigenetics and the Transcriptome
Pfizersomatotropin
Eli Lilly and CompanyTurner Syndrome Prenatal Diagnosis Study

Clinical Trials (8)

Total enrollment: 621 patients across 8 trials

NCT00134745Novo Nordiskestradiol

Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome

Start: Jun 2005Est. completion: Mar 201343 patients
Phase 4Completed
NCT07221851Ascendis PharmaLonapegsomatropin [SKYTROFA®]

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

Start: Dec 2025Est. completion: Mar 2029186 patients
Phase 3Recruiting
NCT00234533IpsenSomatropin

Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq

Start: Jun 2004Est. completion: Jul 2008251 patients
Phase 3Completed
NCT00140998Eli Lilly and Company17 beta estradiol

Estrogen Treatment (Oral vs. Patches) in Turner Syndrome

Start: Jan 2001Est. completion: Jun 200416 patients
Phase 3Completed
NCT05690386Ascendis PharmaLonapegsomatropin

A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome

Start: Feb 2023Est. completion: Dec 202748 patients
Phase 2Active Not Recruiting
NCT01678261AP BiosciencesX-chromosome Inactivation, Epigenetics and the Transcriptome

X-chromosome Inactivation, Epigenetics and the Transcriptome

Start: Sep 2012Est. completion: Jan 2016
N/ACompleted
NCT01367834Pfizersomatotropin

Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome

Start: May 2010Est. completion: May 201417 patients
N/ACompleted
NCT01668251Eli Lilly and CompanyTurner Syndrome Prenatal Diagnosis Study

Turner Syndrome Prenatal Diagnosis Study

Start: Jan 2006Est. completion: Jan 201760 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 621 patients
6 companies competing in this space